Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

China Contract Research Organization (CRO) Industry Report, 2020-2026

Published by ResearchInChina Product code 973124
Published Content info 202 Pages
Delivery time: 1-2 business days
Price
Back to Top
China Contract Research Organization (CRO) Industry Report, 2020-2026
Published: November 17, 2020 Content info: 202 Pages
Description

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the proliferating expenses for pharmaceutical R&D. In 2020, the world CRO market is expected to worth $69.9 billion with a year-on-year spike of 9%.

Competition ever pricks up among at least 1,100 CRO players worldwide led by LabCorp, IQVIA, Syneos, Parexel, PRA, PPD, and Charles River. In 2019, IQVIA, LabCorp and Syneos were the three leaders sweeping a combined market share of 21.5%.

China's great competitive edge over the developed countries in pharmaceutical R&D cost has allured many world-renowned pharmaceutical corporations and boosted the country's CRO industry. With speedy development over a decade, China has been an important CRO market whose market size in 2020 will soar 10.1% on an annualized basis and reach RMB81.6 billion.

In addition to multinational giants represented by IQVIA, LabCorp, Parexel, etc., China also sees local CRO leaders including Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed, and Joinn Laboratories, where Wuxi AppTec with the strongest R&D strength as one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, not only runs the China's largest small-molecule pharmaceutical R&D service business but leads the way in global market. It enjoyed a virtually 12.3% (up 1.8 percentage points over the prior year) of the world's CRO market in 2019.

China's CRO industry will be heading towards:

  • 1) Mergers and acquisitions will still prevail for an industry reshuffle: Seen from the development course of multinational CRO companies, giants expand their business and sharpen edges through M&As, so do the Chinese CRO peers in recent year. In September 2020, Asymchem acquired the CRO company GoalGen for RMB30 million.
  • 2) Chinese CRO companies have landed in the capital market: WuXi AppTec and Pharmaron were listed on the A-share and H-share markets successively. In 2019, Viva Biotech went public on the Hong Kong Stock Exchange. In 2020, HitGen was listed on the A-share market.
  • 3) The industry gears toward vertical integration: Wuxi AppTec, for example, is able to provide customers with integrated new drug R&D and production services, which can help customers save plenty of time and costs as well as improve R&D and production efficiency. Noticeably, the players like Pharmaron, Boji Medical Biotechnological, Porton Pharma Solutions, and Shanghai ChemPartner are expanding to CMO/CDMO.

“China Contract Research Organization (CRO) Industry Report, 2020-2026” highlights:

  • Global CRO industry (development history/environment, market size, competitive landscape, etc.);
  • China CRO industry (development environment, status quo, market size, competition pattern, development trends, etc.);
  • 13 Chinese and 8 foreign companies (revenue, business structure, CRO business, etc.)
Table of Contents

Table of Contents

1. Overview of Pharmaceutical Outsourcing

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 CRO

2. Evolution of Global CRO Industry

  • 2.1 Development History
  • 2.2 Development Background
    • 2.2.1 Pharmaceutical Industry Size
    • 2.2.2 Pharmaceutical Companies Development
    • 2.2.3 Financing
    • 2.2.4 Pharmaceutical R&D
  • 2.3 Market Size
  • 2.4 Competitive Landscape

3. CRO Industry in China

  • 3.1 Development Environment
    • 3.1.1 Regulation
    • 3.1.2 Policy Environment
    • 3.1.3 Industry Environment
  • 3.2 Status Quo
  • 3.3 Market Size
  • 3.4 Competitive Landscape
  • 3.5 Development Trend
    • 3.5.1 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
    • 3.5.2 Favorable policies and capital promote the development of local Chinese companies
    • 3.5.3 Good Prospects Attract the Enterprises' Access into CRO Industry
    • 3.5.4 The Industry Heads toward Vertical Integration
    • 3.5.5 M&A May Become the Main Way for CRO Companies to Expand
    • 3.5.6 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry
    • 3.5.7 Industry threshold and concentration degree rises gradually
    • 3.5.8 Specialization and characterization are becoming ever more obvious

4. Major Chinese Companies

  • 4.1 Wuxi AppTec
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 Major Clients
    • 4.1.6 R&D Investment
    • 4.1.7 CRO Business
    • 4.1.8 Development Strategy
  • 4.2 Hangzhou Tigermed
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Development Strategy
  • 4.3 Guangzhou Boji Pharmaceutical
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Development Strategy
  • 4.4 Shanghai Meidicilon Inc.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Major Clients
    • 4.4.7 Development Strategy
  • 4.5 Porton Fine Chemicals
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D Investment
    • 4.5.6 Major Clients
    • 4.5.7 Development Strategy
  • 4.6 Joinn Laboratories
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Major Clients
    • 4.6.7 Development Strategy
  • 4.7 Pharmaron
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Major Clients
    • 4.7.7 Development Strategy
  • 4.8 Obio Technology (Shanghai)
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Major Clients
    • 4.8.7 Development Strategy
  • 4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Major Clients
    • 4.9.4 Main Business
    • 4.9.5 Development Strategy
  • 4.10 Shanghai ChemPartner
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 Main Business
  • 4.11 HitGen Inc.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Revenue Structure
    • 4.11.4 Gross Margin
    • 4.11.5 R&D Investment
    • 4.11.6 Major Clients
  • 4.12 BioDuro
    • 4.12.1 Profile
    • 4.12.2 Development Course
    • 4.12.3 R&D Center
    • 4.12.4 Development Dynamics
  • 4.13 VIVA Biotech
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 R&D Investment

5 Major Foreign Companies

  • 5.1 LabCorp
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 CRO Business
    • 5.1.5 Development in China
  • 5.2 IQVIA
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Revenue Structure
    • 5.2.4 Development Strategy
    • 5.2.5 Development in China
  • 5.3 Parexel
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Revenue Structure
    • 5.3.4 Dynamics
    • 5.3.5 Development in China
  • 5.4 Charles River
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 Revenue Structure
    • 5.4.4 Development in China
  • 5.5 PPD
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 Revenue Structure
    • 5.5.4 Development in China
    • 5.5.5 Excel PharmaStudies
  • 5.6 Syneos Health
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 Revenue Structure
    • 5.6.4 CRO Business
    • 5.6.5 Development in China
  • 5.7 PRA
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 Revenue Structure
    • 5.7.4 Development in China
  • 5.8 ICON
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 Revenue Structure
    • 5.8.4 Development in China
Back to Top